Clinical trials: in Hong Kong
Hereditary Angioedema (HAE)
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of once-daily orally administered deucrictibant extended-release tablet compared to placebo for prophylaxis to…
- Trial name
- CHAPTER-3 (NCT06669754)
- Testing
- Deucrictibant
- Where
- 56 sites in United States, Argentina and 22 more
- Volunteers
- 85 people
- Sponsor
- Pharvaris Netherlands B.V.
Transcranial Direct Current Stimulation, Autistic Spectrum Disorder
Cumulative and Booster Effects of Multisession Prefrontal tDCS in ASD Adolescents
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by disturbances in communication, poor social skills, and aberrant behavior.
- Conditions
- Transcranial Direct Current Stimulation, Autistic Spectrum Disorder, Electroencephalography
- Trial name
- NCT06272669
- Testing
- Active-tDCS
- Where
- Hong Kong
- Volunteers
- 90 people
- Sponsor
- The Hong Kong Polytechnic University
3-nil Buildings Seniors
Pilot Project on Enhancing Support for Hidden Elderly in the Three-nil Buildings and Old Tenement Buildings: Capacity Building & Impact Evaluation
The aims of this interventional study are of two-fold. First, the study aims to develop the capacity to facilitate the collaborating NGOs to address the social determinants of aging well for 3-N seniors.
- Trial name
- NCT07920328
- Testing
- Mapped intervention based on health status
- Where
- Hong Kong
- Volunteers
- 1,520 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Focal Segmental Glomerulosclerosis
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
PODOMOUNT-pFSGS This study is open to adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT07220083
- Testing
- BI 764198
- Where
- 315 sites in United States, Argentina and 38 more
- Volunteers
- 286 people
- Sponsor
- Boehringer Ingelheim
Arrhythmia, Bradycardia
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival…
- Conditions
- Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
- Trial name
- PPR (NCT00271180)
- Testing
- Device
- Where
- 338 sites in United States, Australia and 33 more
- Volunteers
- 20,000 people
- Sponsor
- Medtronic
Bronchiectasis
A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)
This study is for adults and adolescents who are at least 12 years old and have bronchiectasis. People can participate if they completed a previous study with the study medicine called verducatib.
- Trial name
- NCT07915219
- Testing
- verducatib
- Where
- 383 sites in United States, Argentina and 37 more
- Volunteers
- 1,500 people
- Sponsor
- Boehringer Ingelheim
Ventricular Tachyarrhythmia
Lead EvaluAtion for Defibrillation and Reliability (LEADR) / Lead Evaluation for Defibrillation and Reliability in Left Bundle Branch Area Pacing (LEADR LBBAP)
The LEADR study is designed to assess the safety and efficacy of the Next Generation ICD lead. The LEADR LBBAP study is being conducted under the existing US FDA Investigational Device Exemption (IDE) for the Next Generation ICD…
- Trial name
- NCT04863664
- Testing
- Defibrillation (RV Implant), Defibrillation (LBBAP Implant)
- Where
- 55 sites in United States, Australia and 18 more
- Volunteers
- 1,007 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Psychological Distress, Insomnia
Clinical Trial for Acupuncture in Adolescents With Psychological Distress and Insomnia
This is an assessor-blinded, randomized, MAS-controlled trial. A total of 148 adolescents aged 15-22 years experiencing mild to moderate anxiety or depressive symptoms will be recruited.
- Trial name
- NCT06638450
- Testing
- Dense Cranial Electroacupuncture Stimulation plus Body Acupuncture (DCEAS+BA), Minimal Acupuncture Stimulation (MAS)
- Where
- Hong Kong
- Volunteers
- 148 people
- Sponsor
- The University of Hong Kong
Autism, Social Communication
Parent-implemented Social Communication Treatment in Autism
An accumulation of research evidence has pointed to parent-implemented communication intervention as effective in reducing the severity of social communication deficits in autistic preschoolers.
- Conditions
- Autism, Social Communication, Speech Therapy, Parenting
- Trial name
- NCT05635760
- Testing
- Group-based Parent-implemented Social Communication Training, Self-learning-based Parent-implemented Social Communication Training
- Where
- 2 sites in China, Hong Kong
- Volunteers
- 112 people
- Sponsor
- Chinese University of Hong Kong
Autism Spectrum Disorder, Autism
Parent-implemented Social Communication Treatment in Preschool Children With Autism Spectrum Disorder
An accumulation of research evidence has pointed to parent-implemented communication treatment as effective in reducing the severity of social communication deficits in preschool children with ASD.
- Conditions
- Autism Spectrum Disorder, Autism, Social Communication, Speech Therapy
- Trial name
- NCT05455411
- Testing
- Group-based Parent-implemented Training, Individual-based Parent-implemented Training
- Where
- 2 sites in Hong Kong
- Volunteers
- 144 people
- Sponsor
- Chinese University of Hong Kong
Crohn's Disease
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease.
- Trial name
- NCT06430801
- Testing
- IV Tulisokibart, SC Tulisokibart
- Where
- 499 sites in United States, Australia and 45 more
- Volunteers
- 1,200 people
- Sponsor
- Merck Sharp & Dohme LLC
Influenza Virus, Coronavirus
Tropism and Pathogenesis of Influenza Virus and Coronavirus in Human Brain Explant Culture
Background: Influenza and coronavirus have been repeatedly causing pandemic recently. Like the Influenza A/H7N9 virus has caused five epidemics in China since its first detection in East China in 2013.
- Trial name
- COVID-19 (NCT05375006)
- Where
- Hong Kong
- Volunteers
- 4 people
- Sponsor
- Chinese University of Hong Kong
GIST and CML
Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
This Phase IV, open-label, multicenter roll-over study evaluated the long-term safety of imatinib in patients who had completed a previous Novartis-sponsored imatinib study and were considered by the investigator to continue…
- Trial name
- NCT01742299
- Testing
- imatinib mesylate
- Where
- 29 sites in United States, China and 9 more
- Volunteers
- 155 people
- Sponsor
- Novartis Pharmaceuticals
Bronchiectasis
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is open to adults and adolescents aged 12 to under 18 with bronchiectasis. People can participate in this study if they produce sputum and have had flare-ups (also called exacerbations).
- Trial name
- NCT06872892
- Testing
- BI 1291583
- Where
- 478 sites in United States, Argentina and 44 more
- Volunteers
- 1,755 people
- Sponsor
- Boehringer Ingelheim
Voiding Dysfunction, Substance Abuse
Treatment Outcomes Under a Standardized Treatment Protocol in Patients Suffered Substance Abuse Related Voiding Dysfunction
With the increase of substance abuse over the world, substance abuse e.g. ketamine and methamphetamine related voiding dysfunction is becoming an important medical problem.
- Trial name
- NCT03913819
- Testing
- First line treatment: oral NSAID and anticholinergic agents, Second line treatment: additional treatment for pain control, Third line treatment: A course of intravesical hyaluronate will be given.
- Where
- Hong Kong
- Volunteers
- 1,500 people
- Sponsor
- Chinese University of Hong Kong
Glycogen Storage Disease Type II, Pompe Disease
Pompe Disease Registry Protocol
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both…
- Trial name
- NCT00231400
- Where
- 282 sites in United States, Argentina and 42 more
- Volunteers
- 2,000 people
- Sponsor
- Genzyme, a Sanofi Company
Acute Kidney Injury, Fluid Overload
Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0
There is a growing focus on short- and long-term kidney health in neonates, including those with acute kidney injury (AKI). AKI occurs commonly in the Neonatal Intensive Care Unit (NICU) and is associated with adverse outcomes.
- Conditions
- Acute Kidney Injury, Fluid Overload, Prematurity Complications, Risk Factors
- Trial name
- AWAKEN 2 (NCT06823115)
- Where
- 125 sites in United States, Argentina and 31 more
- Volunteers
- 8,000 people
- Sponsor
- Indiana University
Hemophilia A, Hemophilia B
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
Study B7841007 is an open-label extension study to assess the long-term safety, tolerability, and efficacy of prophylaxis treatment with marstacimab in participants who did not require "Early Termination" from the Phase 3 Study…
- Trial name
- NCT05145127
- Testing
- PF-06741086
- Where
- 78 sites in United States, Argentina and 22 more
- Volunteers
- 245 people
- Sponsor
- Pfizer
Paroxysmal Nocturnal Hemoglobinuria
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
A study designed to evaluate the safety of crovalimab with eculizumab in participants with PNH currently treated with complement inhibitors. This study will enroll approximately 190 participants.
- Trial name
- COMMODORE 1 (NCT04432584)
- Testing
- Crovalimab, Eculizumab
- Where
- 80 sites in United States, Belgium and 22 more
- Volunteers
- 190 people
- Sponsor
- Hoffmann-La Roche
Obstructive Sleep Apnea
Mucosal Inflammation in Children With OSA
Objectives: Variability of clinical phenotypes in childhood obstructive sleep apnoea (OSA) has prompted research for biomarkers to identify patients at risk of developing OSA-related complications.
- Trial name
- NCT06452979
- Where
- Hong Kong
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong